Recently, many companies have been releasing their Q4 2024 financial reports. Have the @WallStreet_Tiger community noticed any companies with astonishing financial results?
Today, Wallstreet_Tiger has selected 5 stocks with significant gains to introduce to our fellow investors. These companies are spread across various industries:
Biotechnology: $PepGen Inc.(PEPG)$
Biopharmaceuticals: $Bridge Investment Group Holdings Inc.(BRDG)$
Educational Services and Technical Skills Training: $Lincoln Educational(LINC)$
Apparel and Accessories: $Canada Goose(GOOS)$
Healthcare: $GRAIL, Inc.(GRAL)$
The chart below shows the stock price gains of these five companies as of yesterday's close, as well as their Q4 2024 EPS and revenue, compared to expectations.
Business: PepGen Inc. is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurological diseases.
Latest News:
PepGen's stock price fell to a 52-week low of $1.16, with market challenges intensifying.
PepGen is advancing its PGN-EDO51 CONNECT clinical program, a therapeutic trial for severe neuromuscular diseases.
The FDA has halted PepGen's DMD trial; ongoing studies continue.
$Bridge Investment Group Holdings Inc.(BRDG)$
Business: BridgeBio Pharma is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines to treat genetic diseases and cancers. The company achieves this by establishing multiple subsidiaries, each focusing on one or more related diseases or product candidates.
Financial Performance:
Q4 and full-year revenue were not explicitly disclosed, but the company's overall financial condition is sound.
Significant commercial progress has been made with Attruby™ (acoramidis), with 1,028 prescriptions filled since FDA approval.
The company has ample cash reserves, with $683 million in cash and cash equivalents as of the end of 2024.
Future Outlook:
BridgeBio Pharma plans to receive regulatory milestone payments from Europe and Japan in the first half of 2025 and continue advancing multiple clinical programs.
The company may receive approvals, rejections, or requests for additional data from the FDA or other regulatory agencies, all of which could impact its stock price.
Clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for genetic diseases and cancers.
Business: Lincoln Educational Services Corporation is a leading vocational training company, offering educational and training services across multiple fields, including automotive technology, culinary arts, healthcare, information technology, and business. The company provides practical skills and theoretical knowledge to students through its campuses across the United States and online platforms, helping them obtain professional qualifications and enhance their employment opportunities.
Business: GOOS is a company focused on luxury outerwear.
Financial Performance:
Canada Goose Holdings' Q4 earnings exceeded analyst expectations, but revenue fell short, causing the stock price to decline in trading.
Canada Goose Holdings' Q4 EPS and revenue exceeded expectations.
Canada Goose's stock price fell due to new U.S. tariff policies.
Canada Goose's Q2 performance was mixed, with a strategic transformation underway.
Business: GRAIL, Inc. is a company focused on multi-cancer early detection, with its core product being the Galleri blood test, capable of detecting over 50 types of cancers. GRAIL's Q4 revenue increased by 26%, driving its stock price higher.
Financial Performance:
Q4 revenue grew by 26% year-over-year, reaching $38.3 million.
Full-year revenue reached $125.6 million, a 35% increase from 2023.
Q4 net loss decreased by 48%, with a full-year net loss of $2 billion.
Future Outlook:
Sales of the Galleri test continue to grow, with plans to publish registration study results and complete modular PMA submissions in 2025 and 2026.
The company has a strong cash position, with $766.8 million in cash and cash equivalents as of the end of 2024, and expects reduced cash burn in 2025.
The recent surge in stock price is related to the Trump administration's "Stargate" plan, which proposes using AI and gene sequencing to develop cancer vaccines, enhancing market confidence in GRAIL's technology.
Summary:
$PepGen Inc.(PEPG)$ : Facing market challenges, but clinical programs are still advancing.
$Bridge Investment Group Holdings Inc.(BRDG)$ : Sound financial condition with significant commercial progress of its drugs.
$Lincoln Educational(LINC)$: Stable market demand as a leading player in the vocational training sector.
$Canada Goose(GOOS)$ : Earnings exceeded expectations, but revenue fell short, with a strategic transformation underway.
$GRAIL, Inc.(GRAL)$ : Significant revenue growth, sound financial condition, and an optimistic future outlook.
Feel free to share your thoughts on the future trends of these stocks in the comments section, and we'd love to hear about other stocks with growth potential! 🎉
A tool to boost your purchasing power and trading ideas with CashBoost!
Open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Comments
Great article, would you like to share it?